Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis

Cancer Biology and Therapy

Volumn 12, Issue 7, 2011, Pages 586-597

  Paradziej Łukowicz, Jolanta ^a,b   Skwarska, Anna ^a,b   Peszyńska Sularz, Grazyna ^a,b   Brillowska Da̧browska, Anna ^a   Konopa, Jerzy ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Angiogenesis; Chemotherapy; HIF 1; Hypoxia; Imidazoacridinone C 1311; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMIDACRINE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HCT116; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; FEMALE; GENETIC TRANSCRIPTION; GENOTYPE; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION;

AMINOACRIDINES; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; CELL-FREE SYSTEM; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MELANOMA; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RESPONSE ELEMENTS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052898350     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.7.15980     Document Type: Article

References (49)

1. Cholody WM, Martelli S, Konopa J. Chromophoremodified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 1992; 35:378-82; PMID:1732555; DOI:10.1021/ jm00080a026.
2. Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, et al. Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. Eur J Cancer 2010; 46:729-34; PMID:20031390; DOI:10.1016/j.ejca.2009.12.005.
3. Capizzi RL, Roman LA, Tjulandin S, Smirnova I, Manikhas A, Paterson JS, et al. Phase II trial of C-1311, a novel inhibitor of topoisomerase II in advanced breast cancer. J Clin Oncol 2006; 26:1055.
4. Burger AM, Jenkins TC, Double JA, Bibby MC. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C-1311. Br J Cancer 1999; 81:367-75; PMID:10496367; DOI:10.1038/sj.bjc.6690702.
5. Dziegielewski J, Slusarski B, Konitz A, Skladanowski A, Konopa J. Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumour activity. Biochem Pharmacol 2002; 63:1653-62; PMID:12007568; DOI:10.1016/S0006-2952(02)00916-4.
6. Dziegielewski J, Konopa J. Characterization of covalent binding to DNA of antitumor imidazoacridinone C-1311, after metabolic activation. Ann Oncol 1999; 9:137.
7. Dziegielewski J, Konopa J. Interstrand crosslinking of DNA induced in tumor cells by a new group of antitumor imidazoacridinones. AACR Meeting Abstracts 1996; 37:410.
8. Konopa J, Koba M, Dyrcz A. Interstrand crosslinking of DNA by C-1311 (Symadex) and other imidazoacridinones. AACR Meeting Abstracts 2005; 46:1382.
9. Skladanowski A, Plisov SY, Konopa J, Larsen AK. Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 1996; 49:772-80; PMID:8622625.
10. Skwarska A, Augustin E, Konopa J. Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311. Apoptosis 2007; 12:2245-57; PMID:17924195; DOI:10.1007/s10495-007-0144-y.
11. 2 phase of L1210 cells. Cancer Chemother Pharmacol 1996; 38:39-44; PMID:8603450; DOI:10.1007/ s002800050445.
12. Skwarska A, Augustin E, Konopa J. Apoptosis of human leukemia cells induced by imidazoacridinone derivative C-1311 (Symadex). Acta Biochim Pol 2005; 52:143.
13. Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG, Double JA. Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C-1311 in human tumour cell lines. Eur J Cancer 2001; 37:1953-62; PMID:11576853; DOI:10.1016/ S0959-8049(01)00227-1.
14. Hyzy M, Bozko P, Konopa J, Skladanowski A. Antitumour imidazoacridinone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 2005; 69:801-9; PMID:15710357; DOI:10.1016/j.bcp.2004.11.028.
15. De Marco C, Zaffaroni N, Comijn E, Tesei A, Zoli W, Peters GJ. Comparative evaluation of C1311 cytotoxic activity and interference with cell cycle progression in panel of human solid tumor and leukemia cell lines. Int J Oncol 2007; 31:907-13; PMID:17786324.
16. Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, et al. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia 2011; 13:72-80.
17. Nolan KA, Humphries MP, Bryce RA, Stratford IJ. Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2. Bioorg Med Chem Lett 2010; 20:2832-6; PMID:20356739; DOI:10.1016/j. bmcl.2010.03.051.
18. Chau M, Otake Y, Christensen JL, Fernandes DJ, Ajami AM. The imidazoacridinone, C-1311 (SymadexTM): The first of a potent new class of FLT3 inhibitors. AACR Meeting Abstracts 2006; 2006:35.
19. Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, et al. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc Natl Acad Sci USA 2005; 102:16741-6; PMID:16272221; DOI:10.1073/pnas. 0506088102.
20. Karlik SJ, Ajami A. Symadex, a tyrosine kinase inhibitor, shows effectiveness in experimental autoimmune encephalomyelitis. Mult Scler 2006; 12:226.
21. Lemke K, Wojciechowski M, Laine W, Bailly C, Colson P, Baginski M, et al. Induction of unique structural changes in guanine-rich DNA regions by the triazoloacridone C-1305, a topoisomerase II inhibitor with antitumor activities. Nucleic Acids Res 2005; 33:6034-47; PMID:16254080; DOI:10.1093/nar/gki904.
22. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721-32; PMID:13130303; DOI:10.1038/nrc1187.
23. Blagosklonny MV. Hypoxia-inducible factor: Achilles'heel of antiangiogenic cancer therapy. Int J Oncol 2001; 19:257-62; PMID:11445836.
24. Brahimi-Horn C, Mazure N, Pouyssegur J. Signaling via the hypoxia-inducible factor-1 alpha requires multiple posttranslational modifications. Cell Signal 2005; 17:1-9; PMID:15451019; DOI:10.1016/j.cellsig. 2004.04.010.
25. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxiainducible factor 1. Mol Cell Biol 1996; 16:4604-13; PMID:8756616.
26. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007; 12:853-9; PMID:17933687; DOI:10.1016/j. drudis.2007.08.006.
27. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumor activity. Nat Rev Cancer 2008; 8:579-91; PMID:18596824; DOI:10.1038/nrc2403.
28. Brahimi-Horn MC, Chiche J, Pouyssegur J. Hypoxia and cancer. J Mol Med 2007; 85:1301-7; PMID:18026916; DOI:10.1007/s00109-007-0281-3.
29. Kimura H, Weisz A, Karashima Y, Hashimoto K, Ogura T, D'Acqusto F, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000; 95:189-97; PMID:10607702.
30. Chan DA, Sutphin PD, Denko NC, Giaccia AJ. Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1α. J Biol Chem 2002; 277:40112-7; PMID:12186875; DOI:10.1074/jbc. M206922200.
31. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581-611; PMID:15294883; DOI:10.1210/er.2003-0027.
32. Ashcroft M, Taya Y, Vousden KH. Stress signals utilize multiple pathways to stabilize p53. Mol Cell Biol 2000; 20:3224-33; PMID:10757806; DOI:10.1128/ MCB.20.9.3224-33.2000.
33. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxiainducible factor 1 alpha. Genes Dev 2000; 14:34-44; PMID:10640274.
34. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JH, et al. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin and fibroblast growth factor. Lab Invest 1992; 67:519-28; PMID:1279270.35.
35. Browder T, Butterfield CE, Kräling BM, Shi B, Marshal B, O'Reilly MS, et al. Antiangiogenic schedule of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175.
36. Hoffmann J, Schirner M, Menrad A, Schneider MR. A high sensitive model for quantification of in vivo tumor angiogenesis induced by alginate- encapsulated tumor cells. Cancer Res 1997; 57:3847-51; PMID:9288798.
37. Wang GL, Semenza GL. Characterization of hypoxiainducible factor 1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268:21513-8; PMID:8408001.
38. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 2003; 112:193-205; PMID:12553908; DOI:10.1016/ S0092-8674(02)01284-9.
39. Schmid T, Zhou J, Brune B. HIF-1 and p53: Communications of transcription factors under hypoxia. J Cell Mol Med 2004; 8:423-31; PMID:15601571; DOI:10.1111/j.1582-4934.2004.tb00467.x.
40. Duyndam MCA, van Berkel MPA, Dorsman JC, Rockx DAP, Pinedo HM, Boven E. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially downregulate hypoxiainducible factor 1 activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74:191-201; PMID:17498666; DOI:10.1016/j.bcp.2007.04.003.
41. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: a new role of the guardian of the genome. J Mol Med 2007; 85:1175-86; PMID:17589818; DOI:10.1007/s00109-007-0221-2.
42. Ryuto M, Ono M, Izumi H, Yoshida S, Weich HA, Kohna M, et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J Biol Chem 1996; 271:28220-8; PMID:8910439; DOI:10.1074/ jbc.271.45.28220.
43. Cummins EP, Taylor CT. Hypoxia-responsive transcription factors. Pflugers Arch 2005; 450:363-71; PMID:16007431; DOI:10.1007/s00424-005-1413-7.
44. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2:727-39; PMID:12360276; DOI:10.1038/nrc905.
45. Quesada AR, Medina MA, Alba E. Playing only one instrument may be not enough. Limitations and future of the antiangiogenic treatment of cancer. Bioessays 2007; 29:1159-68; PMID:17935210; DOI:10.1002/ bies.20655.
46. Petrelli A, Giordano S. From single-to multitarget drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008; 15:422-32; PMID:18288997; DOI:10.2174/092986708783503212.
47. Bunz F, Dutriaux A, Lengauger C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998; 282:1497-501; PMID:9822382; DOI:10.1126/science. 282.5393.1497.
48. Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells expose to prostaglandin E2 is mediated by hypoxiainducible factor 1. Cancer Res 2003; 63:2330-4; PMID:12727858.
49. Kim J, Shao Y, Kim SY, Kim S, Song HK, Jeon JH, et al. Hypoxia-induced IL-18 increases hypoxia-inducible factor-1α expression through a Rac1-dependent NFκB pathway. Mol Biol Cell 2008; 19:433-44; PMID:18003981; DOI:10.1091/mbc.E07-02-0182.